Promotional price valid on web orders only. Your contract pricing may differ. Interested in signing up for a dedicated account number?
Learn More
  1. Home
  2. Products
  3. 5000409017

Medchemexpress LLC Ramipril (HOE-498) | 87333-19-5 | 99.4% | 1 ML
SDP

Catalog No. 5000409017
Encompass_Preferred

Ramipril (HOE-498) is an angiotensin-converting enzyme (ACE) inhibitor with an IC50 of 5 nM. It enhances the activity of ACE-associated CK2 and the phosphorylation of ACE Ser1270 in cultured endothelial cells. Chronic in vivo administration to rats significantly reduces LPS-induced apoptosis. It inhibits systolic blood pressure (SBP) with an IC50 of 1.97 mg/kg in spontaneously hypertensive rats (SHR).

  • Potent angiotensin-converting enzyme (ACE) inhibitor
  • Enhances ACE-associated CK2 activity
  • Reduces LPS-induced apoptosis in rats
  • Inhibits systolic blood pressure (SBP)
  • For research use only

Catalog No. 50-004-09017 Supplier Medchemexpress LLC Supplier No. HYB027910MM/1ML
May include imposed supplier surcharges.
Add to Cart
Add to Cart

missing translation for 'validMainframeMsg'

Ramipril (HOE-498) is an angiotensin-converting enzyme (ACE) inhibitor with an IC50 of 5 nM. It enhances the activity of ACE-associated CK2 and the phosphorylation of ACE Ser1270 in cultured endothelial cells. Chronic in vivo administration to rats significantly reduces LPS-induced apoptosis. It inhibits systolic blood pressure (SBP) with an IC50 of 1.97 mg/kg in spontaneously hypertensive rats (SHR).

  • Potent angiotensin-converting enzyme (ACE) inhibitor
  • Enhances ACE-associated CK2 activity
  • Reduces LPS-induced apoptosis in rats
  • Inhibits systolic blood pressure (SBP)
  • For research use only

Product Title
Select an issue

By clicking Submit, you acknowledge that you may be contacted by Fisher Scientific in regards to the feedback you have provided in this form. We will not share your information for any other purposes. All contact information provided shall also be maintained in accordance with our Privacy Policy.